Clinical trial · Observational
Omics of Cancer: OncoGenomics
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): No participants enrolled
Summary
Brief summary (as posted)
Background: Cancer is a leading cause of death in the United States. Researchers want to know more about how cancer develops and grows. They want to understand more about cancers that run in families. This information will help them find better ways to diagnose and treat cancer. Researchers need to collect data from many people who either have cancer or who may get cancer. Objective: To establish a registry of data about people with cancer. The natural history registry will be linked to a database with information about their genetics. Eligibility: People aged 4 weeks and older with a diagnosis of any cancer. People with precancerous conditions or with a family history of an inherited cancer are also needed. Design: Participants will answer questions about their medical history. This visit can be in-person or by phone. Participants will provide blood and saliva samples. Researchers will also collect any samples the participants may already have given in the past. These may include tumor biopsies or samples of bone marrow or other body fluids. No blood will be collected from children younger than 3 years. No new surgeries or biopsies will be done for this study. The samples will be used for genetic research. Researchers will follow up with participants once a year. They will get an updated medical history. They will ask for any new biopsies or other tissue samples. They may collect new saliva and blood samples. Participants may continue in the study for the rest of their lives....
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Cohort 1
- description
- Participants with cancer or cancer predisposition
Primary outcomes (1)
- measure
- establish a registry in which clinical data of participants with cancer or cancer predisposition is linked to the genomic database of analyzed samples
- timeFrame
- 20 yrs
- description
- perform systematic genetic and genomic analysis to enrolled participants treated at the Center for Cancer Research (CCR, NCI) and all Divisions of NCI for the identification of biomarkers and targets of potential therapeutic actionability
Secondary outcomes (3)
- measure
- determine the feasibility of longitudinal collection and analyses of liquid biopsies alongside the analysis of matched tumor samples
- timeFrame
- Ongoing throughout study
- description
- to characterize heterogeneity and to identify therapeutically resistant clones
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 4 Weeks
Show eligibility criteria text
* INCLUSION CRITERIA: * Age \>= 4 weeks * Participants must have: * diagnosis of any tumor, malignancy, pre-malignant disorder OR * evidence of an inherited cancer syndrome based on family history and/or other manifestations of the syndrome (i.e., polyposis, plexiform neurofibromas, myelodysplastic syndrome) -Participants must * have biospecimen (e.g., tumor, normal, blood, bone marrow, serum, plasma, or any other specimen) that has been previously collected and is available for research analysis OR --be scheduled to undergo surgery or biopsy for routine patient care on another research or standard of care protocol OR --be willing to provide blood and/or saliva specimens. Note: does not apply to children \< 3 years old -The ability of participant or parent/guardian to understand and the willingness to sign a written consent document. EXCLUSION CRITERIA: None
References
Publications (0)
Data not yet available